Bolenz, C <br/><br/>
[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].  [electronic resource] 

 -  Aktuelle Urologie  Jan 2009 
 - 31-6 p.  digital 
<br/><br/> Publication Type: Comparative Study; Evaluation Study; Journal Article 
<br/><br/><label>ISSN: </label>1438-8820 
<br/><br/><label>Standard No.: </label>10.1055/s-2008-1038176  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Benzenesulfonates--administration & dosage<br/>Carcinoma, Renal Cell--drug therapy<br/>Clinical Trials, Phase III as Topic<br/>Cohort Studies<br/>Data Interpretation, Statistical<br/>Female<br/>Germany<br/>Humans<br/>Indoles--administration & dosage<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Medical Oncology<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Protein Kinase Inhibitors--administration & dosage<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyridines--administration & dosage<br/>Pyrroles--administration & dosage<br/>Sorafenib<br/>Sunitinib<br/>Surveys and Questionnaires<br/>Time Factors<br/>Urology